Physician profile
Daniel Meadows
NPI 1588619662
$1,085.86
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.01 · 2020: $351 · 2021: $215 · 2022: $498.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $337.01 | 2020 | |
| Abbvie INC. | $320.26 | 2021-2022 | |
| Corium, LLC | $93.55 | 2022 | |
| Supernus Pharmaceuticals, INC. | $66.07 | 2022 | |
| Alkermes, INC. | $59.27 | 2022 | |
| Almatica Pharma LLC | $48.47 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.41 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $40.83 | 2021-2022 | |
| Allergan, INC. | $30.53 | 2020-2021 | |
| Neuronetics, INC. | $21.01 | 2019 | |
| Bausch Health US, LLC | $13.73 | 2022 | |
| Axsome Therapeutics, INC. | $13.72 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Meadows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.